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patients with and without dose escalation, respectively, and CDN$29,504 and 
CDN$25,449 for infliximab in patients with and without dose escalation, 
respectively. CONCLUSIONS: Results of this RAMQ database analysis illustrate 
that, in a real-world setting and over a long period of time, CD patients treated 
with infliximab had a significantly higher proportion of dose escalation 
compared with patients treated with adalimumab. In both recommended and 
adjusted dosing, adalimumab demonstrated significant cost savings over 
infliximab.  
 
PGI29  
THE USE OF REPEAT SCREENING COLONOSCOPY IN A NATIONWIDE 
PRIVATELY INSURED POPULATION  
Chu LH, McCombs J 
University of Southern California, Los Angeles, CA, USA  
OBJECTIVES: Assess the frequency and appropriateness of early repeated 
colonoscopy METHODS: Patients undergoing a colonoscopy in 2005 were identified 
using paid claims data from a nationwide privately insured population. Patients 
were screened to be between the ages of 50 and 64 years with at least one year 
continuous enrollment. Colonoscopies with evidence of positive results [e.g., paid 
claims for biopsy, fulguration, snare, etc.], or with evidence suggesting clinical 
indications three months prior to the screening were defined as non-screen tests. 
The cumulative probability of repeated screening colonoscopy was then 
documented and the related risk factors for appropriate and inappropriate repeat 
screening tests were assessed using survival analysis and Cox proportional hazard 
regression models. RESULTS: A total of 51,400 colonoscopies were identified from 
the paid claims in 2005 for patients age 50-64. The majority of these procedures 
were found to have either positive results [25,029 (48.7%)] or evidence of clinical 
indications for the procedure [17,842 (34.7%)]. Among 8,529 apparent screening 
colonoscopies with negative results, 8% had a repeated colonoscopy within six 
years, the majority of which were associated with evidence that the repeated test 
could be justified (78.7% with indications and 21.3% without indications). The initial 
regression analysis identified risk factors of repeated colonoscopy with indications 
including age over 55 (HR: 1.2; 95%CI: 1.0–1.5) and having at least one comorbidity 
(HR: 1.2; 95%CI: 1.0-1.5). The risk factors of repeated colonoscopy without 
indications include male (HR: 1.53; 95%CI: 1.07-2.20) and having at least one 
comorbidity (HR: 1.57; 95%CI: 1.04-2.31). CONCLUSIONS: The majority of all 
colonoscopies in 2005 were found not to be routine screening exams. The risk of a 
repeated screening colonoscopy within 6 years is low [8%]. Among these repeat 
procedures, the majority was done because of the existence of clinical indications.  
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FLUOROQUINOLONE-ASSOCIATED TENDON-RUPTURE: A SUMMARY OF 
REPORTS IN THE FOOD AND DRUG ADMINISTRATION'S (FDA'S) ADVERSE 
EVENT REPORTING SYSTEM  
Arabyat RM1, Garg V2, Raisch DW3, Bennett C4 
1University of New Mexico, Albuqurque, NM, USA, 2University of New Mexico, Albuquerque, 
NM, USA, 3University of New Mexico College of Pharmacy, Albuquerque, NM, USA, 4University 
of South Carolina, Columbia, SC, USA  
OBJECTIVES: Tendon rupture is associated with fluoroquinolones and listed in 
boxed warnings. We reviewed and summarized reports of tendon rupture 
associated with fluoroquinolones as reported in the FDA’s Adverse Event 
Reporting System (FAERS) through September 26, 2012. METHODS: We queried 
the FAERS for reports of tendon rupture involving each fluoroquinolone. Signal 
detection consisted of empiric Bayes geometric mean (EBGM), with 95% 
confidence intervals from initial marketing date for each drug. For a signal to be 
considered significant, minimum criteria are: reports of 3 or more cases, the low 
end of the 95% confidence interval must be 2.0 or greater. RESULTS: There were 
2539 tendon rupture cases. Most cases were reported with levofloxacin (61.25%) 
followed by ciprofloxacin (23.87%) and moxifloxacin (9.05%). Signal detection 
results for fluoroquinolones were: ciprofloxacin (EBGM=20.0, 95%CI=18.2-21.6), 
enoxacin (EBGM=13.2, 95%CI=4.2-29.7), gatifloxacin (EBGM=5.0, 95%CI=3.5-7.0), 
levofloxacin (EBGM=55.2, 95%CI=52.3-58.0), moxifloxacin (EBGM=13.3, 
95%CI=11.7-15.1), norfloxacin (EBGM=9.6, 95%CI=6.5-13.5), ofloxacin (EBGM=8.2, 
95%CI=6.3-10.2), gemifloxacin (EBGM=1.9, 95%CI=0.7-4.5), lomefloxacin 
(EBGM=2.3, 95%CI=0.94-5), and trovafloxacin (EBGM=0.3, 95%CI=0.08-1.1). FAERS 
event date timelines suggest lower risk of tendon rupture for gemifloxacin (n=5), 
lomefloxacin (n=5), and trovafloxan (n=1), with initial reports in 2006, 2005, and 
2000, respectively. The mean age was 59.6± 5.1. The most common concurrent 
drugs were corticosteroids (levofloxacin=27.1%, enoxacin=20%, gatifloxacin 
=18.2%, moxifloxacin=14.7%, ciprofloxacin=10.4%, ofloxacin=5.3%, and 
norfloxacin=2.4%). Analysis by the reporting country revealed that most cases 
were reported from the US (70%) followed by Japan (8.2%), Great Britain (3.7%), 
France (.9%) and Canada (.42%). CONCLUSIONS: Tendon rupture was reported 
with most fluoroquinolones. Significant signals existed for all flouroquinolones 
except gemifloxacin, lomefloxacin, and trovafloxacin, which potentially have 
lower risks. However, FAERS data are dependent upon utilization and MedWatch 
reporting rates. As stated in the boxed warning, as stated in the boxed warning, 
concurrent corticosteroids increases risk of tendon rupture  
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RISK AND COST-EFFECTIVENESS ANALYSIS OF ADVERSE ATRIAL 
FIBRILLATION OUTCOME IN TREATING OSTEOPROSIS  
Kao YH1, Chang LC1, Tsai YW1, Chen LK2, Huang WF1 
1National Yang-Ming University, Taipei, Taiwan, 2Taipei Veterans General Hospital, Taipei, 
Taiwan  
OBJECTIVES: The purpose of this study was to investigate the risk of getting 
atrial fibrillation in a year after receiving the first medication and analyze cost-
effectiveness in avoiding the adverse event among alendronate, raloxifene, and 
hormone replacement therapy. METHODS: We used the 2000-2008 National 
Health Insurance Research Database (NHIRD) to identify 10,353 patients who had 
the first medication with drugs and classify them into three groups (7439 
patients defined as those who used alendronate and 2077 patients with 
raloxifene as well as 837 patients with hormone replacement therapy). Cox 
proportional hazard model was used to estimate the hazards of getting atrial 
fibrillation among three drugs. Also, this study used the cost-effectiveness 
analysis to estimate the incremental cost effective ratio in avoiding the adverse 
event as they were treated by different treatments. RESULTS: The Cox regression 
analyses demonstrated that alendronate group (HR=1.52, 95%CI: 0.55-4.19) and 
raloxifene group (HR=1.38, 95%CI: 0.46-4.21) had higher risk in getting atrial 
fibrillation than hormone replacement therapy group, but there were not 
statistically significant. As to the cost-effectiveness analysis in avoiding 1% 
chance of the adverse event, the average medication expenditure of hormone 
replacement therapy group would increase 2,916.7 USD (ICER=2,916.7, 95%CI: 
1063.3–5,102.9) and 2,266.7 USD (ICER=2,266.7, 95%CI: -411.5–5,068.1), comparing 
to alendronate group and raloxifene group respectively. CONCLUSIONS: People 
with osteoporosis that were treated by bisphosphonate or raloxifene are better in 
terms of overall economic cost than those who used hormone replacement 
therapy.  
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SYSTEMATIC REVIEW AND META-ANALYSIS OF OPEN SPINE FUSION VERSUS 
MINIMALLY INVASIVE SPINE FUSION FOR THE DIAGNOSIS AND TREATMENT 
OF LUMBAR SPINE CONDITIONS  
Cizik AM, Devine EB, Wolf FM, Babigumira JB, Lee MJ 
University of Washington, Seattle, WA, USA  
OBJECTIVES: Transforaminal Lumbar Interbody Fusion is used to treat 
mechanical back-pain and radicular pain associated with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis. This procedure is performed either 
in the traditional open technique (o-TLIF) or using minimally invasive (m-TLIF) 
techniques. The goal of this study was to conduct a meta-analysis to compare 
various outcomes when comparing treatments for lumbar spine conditions using 
the “standard” open fusion (o-TLIF) versus minimally invasive surgical fusion (m-
TLIF). METHODS: Prospective and retrospective cohort studies comparing o-TLIF 
to m-TLIF were identified by searching PubMed, EMBASE, the Cochrane libraries, 
and reference lists from selected studies. Of the 15 selected for full-text review, 4 
were excluded because they used the wrong surgical technique, did not include 
m-TLIF, or did not measure the desired outcomes. Effects sizes (relative risks and 
standardized mean differences) were calculated using both fixed- and random-
effects models. RESULTS: Eleven cohort studies (N=554 patients) were included 
in the review (N=259, o-TLIF; and N=294, m-TLIF). Average follow-up ranged from 
12 – 24 months. Random-effects models were used due to the high heterogeneity 
across studies for each outcome (53.1%-93.5%). Use of m-TLIF was associated 
with a 420 mL decrease in blood loss when compared to o-TLIF (standardized 
mean difference (SMD) = -1.57, 95% CI: -2.14 to -0.99, p<0.0001). Operating Room 
(OR) time was significantly longer with a 33 minute increase for those 
undergoing m-TLIF (SMD=0.90, 95% CI: 0.24 to 1.55, p=0.007). CONCLUSIONS: 
While most outcomes did not differ between the two procedures, m-TLIF was 
associated with significantly lower blood loss despite longer OR time. In the 
appropriate clinical population, m-TLIF may be the favorable TLIF procedure for 
treatment of back pain and radicular pain in patients with spondylolisthesis due 
to arthritis, herniated disc or spinal stenosis.  
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OBJECTIVES: Hip resurfacing (HR) was developed for younger, more active 
patients, as a surgical alternative to total hip arthroplasty (THA). The safety of 
metal-on-metal HR is controversial with concerns expressed over adverse events 
and early device failure. We conducted a systematic review comparing primary 
HR to conventional THA for patients with hip osteoarthritis (OA). Outcomes of 
interest were adverse event rates, early failure (revision/reoperation within 5 
years), and post-operative component alignment. METHODS: Studies were 
identified through electronic databases, grey literature and reference lists of 
included studies. Inclusion criteria were: English language studies published 
after 1996 reporting adverse events, complications, safety issues or revision rates 
with respect to adults with primary hip OA, who underwent either primary HR or 
THA. Outcomes of interest included: revision, reoperation, dislocation, 
infection/sepsis, femoral neck fractures, time to revision, rates of early failure, 
mortality, and post-operative component alignment. Results were reported per 
1000 person years for comparability and stratified by age, publication date and 
market status (in-use and discontinued). RESULTS: A total of 7421 abstracts were 
identified and screened. Of these 384 full text articles were reviewed, 236 of 
which were included in this analysis. For all devices, those in-use and 
discontinued, dislocations were more frequent in THA, while revisions and 
reoperations were more frequent in HR. An analysis of only devices currently in-
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use determined that early revisions/reoperations were more frequent in HR than 
in THA (range 3.1-13.1 vs. 1.9-7.5 per 1000 person years, respectively). 
CONCLUSIONS: This systematic review provides clinicians and health policy 
makers with information on adverse events based on device type and market 
status. Rates of adverse events vary by device type, making it challenging to 
conclude which device is more effective. Findings highlight the importance of 
differentiating market status and standardizing exposure time by 1000 person 
years to facilitate comparisons between studies.  
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ADVERSE EVENTS ASSOCIATED WITH COLCHICINE DRUG INTERACTIONS: 
ANALYSIS OF THE PUBLIC VERSION OF THE FDA ADVERSE EVENT REPORTING 
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OBJECTIVES: Colchicine was originally used, and continues to be used, to treat 
rheumatic diseases. It is used most frequently for the treatment of gout but is 
also used to treat familial Mediterranean fever, pericarditis, and Behcet’s disease. 
However, because of its pharmacokinetics, colchicine can interact dangerously 
with other drugs. The objective of the study was to analyze the association 
between drug-drug interactions involving colchicine and major adverse events 
as reported in the U.S. FDA Adverse Event Reporting System (FAERS). METHODS: 
All major adverse events (including death, initial or prolonged hospitalization, 
and persistent or significant disability) related to colchicine between 2004 and 
2011 were retrieved from FAERS. Then, events evidently caused by interactions 
with drugs (such as atazanavir, clarithromycin, indinavir, itraconazole, 
ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, 
cyclosporine, and ranolazine) were distinguished from events evidently caused 
by colchicine as the primary suspect drug. Major adverse event rates were 
calculated. RESULTS: Between 2004 and 2011, a total of 2655 adverse event 
reports involving colchicine interactions with other drugs were found in the 
FAERS database, of which 718 reported a death (implying a fatality ratio of 
27.0%), 762 reported a hospitalization (giving a 28.7% hospitalization rate), 78 
referred to life-threatening events, and 56 reported disability. Pancytopenia, 
renal failure, vomiting, drug toxicity, and diarrhea were the most common 
reported events. There were 4,717 reports involving colchicine as the primary 
suspect drug, of which 527 reported a death (fatality ratio of 11.2%). A 
statistically significant (p<0.001) difference between the two fatality ratios was 
found. CONCLUSIONS: When combined with certain other drugs, evidence 
suggests that colchicine may be associated with a relatively high death rate, 
especially if not dosed appropriately. In light of the current data, physicians 
should be keenly aware of all potentially fatal drug-drug interactions and follow 
therapeutic guidelines on using colchicine.  
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INTENSIVE CARE UNIT ADMISSION AMONG TRUMA PATIENTS AT A LARGE 
TRAUMA CENTER IN SAUDI ARABIA  
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OBJECTIVES: Despite risk of mortality, traffic-related injuries place a significant 
financial burden on the health sector, especially due to costs like intensive  
care unit (ICU) admission and prolonged hospital stays. The aim of the study is 
to investigate risk factors of admission to the ICU among injured-patients 
admitted to a large urban trauma center in Saudi Arabia. METHODS: This 
analysis was performed using a dataset from King Abdulaziz Medical City  
in Riyadh, Saudi Arabia. 7,859 patients met the inclusion criteria during the 
study period (injured due to falls or traffic crashes and admitted to the hospital 
between years 2001-2010). Backward-stepwise logistic regression, with admission 
to the ICU as the outcome, was performed. Variables with p-values<0.1  
were included in the final model. Model discrimination was evaluated using the 
Area Under the Curve (AUC). RESULTS: A total of 1833 injured individuals (23.3%) 
were admitted into the ICU during the study period. They had longer hospital 
stay and were more likely to be males, sustain head injuries, and to undergo 
surgery. Multivariate analysis identified injury severity score, Glasgow coma 
scale, injury mechanism, head injury, and direct transfer to surgery as 
significant predictors of admission to the ICU. The results indicate that 
compared to falls, all traffic-related injuries were significantly more likely lead to 
ICU admission (occupants OR=2.5, [95% CI: 2.0-3.0]; pedestrians OR=2.7, [95% CI: 
2.1-3.4]; motorcycle OR=1.7, [95% CI: 1.1-2.7]) adjusting for other covariates. The 
model showed excellent discrimination ability as shown by [AUC=0.90]. 
CONCLUSIONS: This model can facilitates the triage process of injured patients 
by assisting in identify those at higher risk of ICU admission. Unlike the U.S, 
emergency health care services are free in Saudi Arabia and costs are mostly 
absorbed by the admitting hospital. Therefore, public health interventions are 
needed to alleviate the burden traffic injuries place on health care settings and 
improve population health.  
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ORAL GLUCOCORTICOID USE IN RITUXIMAB-TREATED RHEUMATOID 
ARTHRITIS PATIENTS WITH PRIOR EXPOSURE TO ANTI-TUMOR NECROSIS 
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OBJECTIVES: Long-term use of oral glucocorticoid (OGC) therapy may be 
associated with adverse effects; thus, OGC-sparing approaches to treatment of 
rheumatoid arthritis (RA) may benefit patients. This study examined OGC use in 
rituximab-treated RA patients with prior exposure to anti-tumor necrosis factor-
alpha (anti-TNF) therapy. METHODS: Administrative claims-based retrospective 
study. Study patients met the following criteria: initiated rituximab between 
March 1, 2006-March 31, 2011 (initiation date=index) after exposure to anti-TNF 
therapy, aged ≥18 years, had a medical claim with a diagnosis code for RA (ICD-9-
CM 714.0x) between January 1, 2004-March 31, 2011, continuously enrolled for 12 
months before and ≥90 days after index, had no medical claims with diagnosis 
codes for non-RA indications of biologic disease modifying antirheumatic drugs 
(BDMARDs) within 12 months before index. Using rituximab infusion dates and 
the recommended administration frequency schedule, rituximab exposure 
periods were constructed. Exposure periods commenced upon index and 
terminated at the first occurrence of switch to a different BDMARD, 90-day gap in 
rituximab treatment, loss to follow-up, or follow-up of 36 months. Outcomes 
were any OGC use and mean daily OGC dose expressed in prednisone equivalent 
and averaged among all patients, measured throughout the exposure period in 
sequential 90-day intervals. Multivariable generalized estimating equation 
models tested for statistically significant changes in OGC use over time. 
RESULTS: Study included 1,763 rituximab exposure periods (1,718 unique 
patients); mean age 54.9 years, 81.5% female, 54.0% with OGC use within 30 days 
before index. Between the first and last 90-day intervals, the probability of OGC 
use and the mean daily OGC dose decreased significantly: from 0.56 to 0.36 
(p<0.001) and from 3.5mg/day to 2.7mg/day (primarily driven by OGC 
discontinuation) (p<0.001), respectively. Sensitivity analyses subset to exposure 
periods lasting a full 36 months yielded similar results. CONCLUSIONS: 
Statistically significant decreases in OGC use were observed in rituximab-treated 
RA patients with prior exposure to anti-TNF therapy.  
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ASSESSMENT OF THE INCIDENCE OF FLARES FOR GOUTY ARTHRITIS PATIENTS 
WITHIN THE SCOTT & WHITE HEALTH CARE SYSTEM  
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OBJECTIVES: To identify features that characterize difficult-to-treat gout patients 
based on the number of flares experienced within a 12-month period. METHODS: 
A retrospective database analysis was conducted using electronic medical 
records, laboratory reports and demographic data files. Eligible patients were 
above 18 years, with at least one diagnosis of gout and/or a gout-related 
medication between January 1, 2005 and December 31, 2010. Patients with at 
least one serum uric acid value and at least one flare were followed for 12 
months from the date the first flare was reported. Eligible patients who had no 
flares within the study period were also included. RESULTS: A total of 266 
patients met study criteria, the mean age (±SD) was 61.2 years (±15.7), the 
majority were males (n=180; 67.7%), the mean annual flare rate was 1.80 (±1.11), 
and the mean serum uric acid value was 7.24mg/dl (±2.07). Based on three 
categories of flare rates, 110 patients (41.4%) had no flares, 107 patients (40.2%) 
had one or two flares, and 49 patients (18.4%) had at least 3 flares. ANOVA tests 
detected significant differences in mean serum uric acid values by flare rate 
(F=18.34; df=2; p<0.0001). Kruskal-Wallis results indicated a significant 
relationship between serum uric acid l ˂evel categories (  6.0 mg/dl, ≥6.0-  ˂9.0 mg/dl 
and ≥9.0 mg/dl) and flare rates; X2=32.26; df=2; p<0.0001. There was no significant 
difference in flare rate by age (F=0.31; df=2; p=0.7355). Although Wilcoxon results 
showed a significant relationship between serum uric acid level categories and 
gender (X2=7.10; df=1; p=0.0077), no significant relationship between flare rates 
and gender (X2=1.67; df=1; p=0.1959) was observed. CONCLUSIONS: More 
information is required to be able to identify and characterize difficult-to-treat 
gout patients.  
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COMPARISON OF DISEASE STATUS AND OUTCOMES OF PATIENTS WITH 
ANKYLOSING SPONDYLITIS (AS) RECEIVING THEIR FIRST BIOLOGIC IN UK, 
GERMANY, FRANCE, ITALY AND SPAIN (5EU)  
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1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK  
OBJECTIVES: To compare the disease status and outcomes of patients with AS 
receiving their first biologic in 5EU. METHODS: A multi-country multi-center 
medical chart-review study of AS patients was conducted among physicians 
(rheumatologists:97%) in hospitals and private practices to collect de-identified 
data on patients who were recently treated with a biologic as part of usual care. 
Physicians were screened for duration of practice (3-30 yrs) and patient volume 
(incl. >5AS biologic patients/month) and recruited from a large panel to be 
geographically representative in each country. Eligible patient charts (>3) were 
randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient 
diagnosis, treatment patterns/dynamics and patient symptomatology/disease 
status/outcomes. RESULTS: In 1Q2012, 1095 eligible AS patient charts were 
abstracted; 935 (85%) patients were on their first biologic (mean-age:42.6yrs, 
female:20%). Geographic distribution of patients were – UK:20%, Germany:18%, 
France/Italy:21%, Spain:19%. Time-to-1st biologic from diagnosis (range:28month 
(Italy)-59month (France)) and time-on-current biologic (range:24month 
(UK/Germany/Italy)-27month (France)) differed within 5EU. Among the top-3 
reasons for biologic treatment initiation, ‘mechanism of action’ & ‘improve 
signs/symptoms’ were observed across 5EU, whereas ‘positive personal 
experience’ (UK/Germany/France) and ‘preservation of structural damage’ 
(Italy/Spain) were also observed. Key lab measures documented were: ESR 
